Overview

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

Status:
Unknown status

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sichuan University

Treatments:

Sorafenib